Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.91
GILD's Cash to Debt is ranked lower than
80% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. GILD: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
GILD' s 10-Year Cash to Debt Range
Min: 0.15   Max: N/A
Current: 0.91

Equity to Asset 0.45
GILD's Equity to Asset is ranked lower than
74% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GILD: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
GILD' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.95
Current: 0.45

0.21
0.95
Interest Coverage 37.05
GILD's Interest Coverage is ranked lower than
86% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 37.05 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s 10-Year Interest Coverage Range
Min: 5.85   Max: 2509.2
Current: 37.05

5.85
2509.2
F-Score: 8
Z-Score: 7.80
M-Score: -2.26
WACC vs ROIC
8.85%
84.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 64.01
GILD's Operating margin (%) is ranked higher than
98% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. GILD: 64.01 )
Ranked among companies with meaningful Operating margin (%) only.
GILD' s 10-Year Operating margin (%) Range
Min: -108.08   Max: 61.33
Current: 64.01

-108.08
61.33
Net-margin (%) 51.69
GILD's Net-margin (%) is ranked higher than
95% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. GILD: 51.69 )
Ranked among companies with meaningful Net-margin (%) only.
GILD' s 10-Year Net-margin (%) Range
Min: -64.97   Max: 48.62
Current: 51.69

-64.97
48.62
ROE (%) 93.90
GILD's ROE (%) is ranked higher than
99% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. GILD: 93.90 )
Ranked among companies with meaningful ROE (%) only.
GILD' s 10-Year ROE (%) Range
Min: -49.14   Max: 90.32
Current: 93.9

-49.14
90.32
ROA (%) 44.09
GILD's ROA (%) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. GILD: 44.09 )
Ranked among companies with meaningful ROA (%) only.
GILD' s 10-Year ROA (%) Range
Min: -30.31   Max: 42.28
Current: 44.09

-30.31
42.28
ROC (Joel Greenblatt) (%) 491.61
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. GILD: 491.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127.04   Max: 484.37
Current: 491.61

-127.04
484.37
Revenue Growth (3Y)(%) 41.70
GILD's Revenue Growth (3Y)(%) is ranked higher than
90% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. GILD: 41.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GILD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.3   Max: 71.8
Current: 41.7

5.3
71.8
EBITDA Growth (3Y)(%) 55.60
GILD's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. GILD: 55.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GILD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.1   Max: 119
Current: 55.6

-9.1
119
EPS Growth (3Y)(%) 60.70
GILD's EPS Growth (3Y)(%) is ranked higher than
95% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. GILD: 60.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GILD' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6   Max: 153.3
Current: 60.7

-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GILD Guru Trades in Q2 2014

Alan Fournier 2,070,000 sh (New)
Ken Heebner 1,710,000 sh (New)
Joel Greenblatt 466,853 sh (New)
Ken Fisher 975,483 sh (+62.11%)
John Rogers 638,734 sh (+60.78%)
Ray Dalio 349,821 sh (+41.22%)
Julian Robertson 443,911 sh (+28.55%)
Pioneer Investments 3,899,022 sh (+16.40%)
Mario Gabelli 49,170 sh (+11.14%)
RS Investment Management 192,614 sh (+6.88%)
John Burbank 3,774 sh (+4.28%)
First Eagle Investment 400 sh (unchged)
Caxton Associates 100,000 sh (unchged)
George Soros Sold Out
David Rolfe Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Jim Simons 166,648 sh (-11.99%)
Paul Tudor Jones 9,304 sh (-13.89%)
Ronald Muhlenkamp 144,715 sh (-24.63%)
Mariko Gordon 11,654 sh (-35.57%)
Vanguard Health Care Fund 1,633,700 sh (-39.79%)
Jeremy Grantham 10,600 sh (-97.95%)
» More
Q3 2014

GILD Guru Trades in Q3 2014

Louis Moore Bacon 11,734 sh (New)
Dodge & Cox 4,800 sh (New)
David Dreman 2,388 sh (New)
Stanley Druckenmiller 217,500 sh (New)
Paul Tudor Jones 30,245 sh (+225.08%)
John Burbank 12,073 sh (+219.90%)
Ronald Muhlenkamp 206,350 sh (+42.59%)
Joel Greenblatt 664,223 sh (+42.28%)
John Rogers 643,896 sh (+0.81%)
Pioneer Investments 3,536,065 sh (unchged)
First Eagle Investment 400 sh (unchged)
Julian Robertson 443,911 sh (unchged)
Jim Simons Sold Out
Ken Heebner 1,560,000 sh (-8.77%)
Alan Fournier 1,861,000 sh (-10.10%)
Mariko Gordon 10,366 sh (-11.05%)
Mario Gabelli 42,600 sh (-13.36%)
RS Investment Management 151,879 sh (-21.15%)
Ken Fisher 763,423 sh (-21.74%)
Ray Dalio 241,521 sh (-30.96%)
Jeremy Grantham 6,700 sh (-36.79%)
Vanguard Health Care Fund 379,200 sh (-76.79%)
» More
Q4 2014

GILD Guru Trades in Q4 2014

Steven Cohen 1,061,100 sh (New)
Jim Simons 941,400 sh (New)
Leon Cooperman 612,500 sh (New)
First Eagle Investment 1,315,088 sh (+328672.00%)
Paul Tudor Jones 109,372 sh (+261.62%)
John Burbank 37,750 sh (+212.68%)
Ray Dalio 537,321 sh (+122.47%)
Joel Greenblatt 1,009,462 sh (+51.98%)
RS Investment Management 190,460 sh (+25.40%)
John Rogers 802,803 sh (+24.68%)
Julian Robertson 533,911 sh (+20.27%)
Alan Fournier 2,141,000 sh (+15.05%)
Ronald Muhlenkamp 218,945 sh (+6.10%)
Ken Fisher 771,501 sh (+1.06%)
Mario Gabelli 42,600 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
First Eagle Investment 1,200 sh (unchged)
Ken Heebner Sold Out
Mariko Gordon Sold Out
Vanguard Health Care Fund Sold Out
Stanley Druckenmiller Sold Out
David Dreman Sold Out
Louis Moore Bacon Sold Out
Dodge & Cox 4,510 sh (-6.04%)
Pioneer Investments 3,180,990 sh (-10.04%)
Jeremy Grantham 4,600 sh (-31.34%)
» More
Q1 2015

GILD Guru Trades in Q1 2015

David Dreman 5,580 sh (New)
John Buckingham 45,281 sh (New)
Lee Ainslie 2,650 sh (New)
Louis Moore Bacon 44,389 sh (New)
Murray Stahl 8,700 sh (New)
NWQ Managers 113,100 sh (New)
Jim Simons 4,032,048 sh (+328.30%)
John Burbank 45,652 sh (+20.93%)
Mario Gabelli 49,470 sh (+16.13%)
John Rogers 891,645 sh (+11.07%)
Joel Greenblatt 1,107,732 sh (+9.73%)
Steven Cohen 1,158,000 sh (+9.13%)
Ken Fisher 789,615 sh (+2.35%)
NWQ Managers 55,200 sh (unchged)
Jeremy Grantham 4,600 sh (unchged)
Leon Cooperman Sold Out
Alan Fournier Sold Out
Ronald Muhlenkamp 218,740 sh (-0.09%)
Pioneer Investments 3,046,688 sh (-4.22%)
Dodge & Cox 4,250 sh (-5.76%)
RS Investment Management 144,820 sh (-23.96%)
Julian Robertson 231,511 sh (-56.64%)
Paul Tudor Jones 6,535 sh (-94.02%)
Ray Dalio 25,221 sh (-95.31%)
First Eagle Investment 400 sh (-99.97%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.60
GILD's P/E(ttm) is ranked higher than
91% of the 279 Companies
in the Global Biotechnology industry.

( Industry Median: 39.60 vs. GILD: 12.60 )
Ranked among companies with meaningful P/E(ttm) only.
GILD' s 10-Year P/E(ttm) Range
Min: 9.69   Max: 45.41
Current: 12.6

9.69
45.41
Forward P/E 10.02
GILD's Forward P/E is ranked higher than
86% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 21.19 vs. GILD: 10.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 12.70
GILD's PE(NRI) is ranked higher than
91% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 38.10 vs. GILD: 12.70 )
Ranked among companies with meaningful PE(NRI) only.
GILD' s 10-Year PE(NRI) Range
Min: 9.68   Max: 45.49
Current: 12.7

9.68
45.49
P/B 9.80
GILD's P/B is ranked lower than
79% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. GILD: 9.80 )
Ranked among companies with meaningful P/B only.
GILD' s 10-Year P/B Range
Min: 4.16   Max: 18.59
Current: 9.8

4.16
18.59
P/S 6.60
GILD's P/S is ranked higher than
69% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.45 vs. GILD: 6.60 )
Ranked among companies with meaningful P/S only.
GILD' s 10-Year P/S Range
Min: 3.48   Max: 14.41
Current: 6.6

3.48
14.41
PFCF 10.90
GILD's PFCF is ranked higher than
89% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. GILD: 10.90 )
Ranked among companies with meaningful PFCF only.
GILD' s 10-Year PFCF Range
Min: 8.33   Max: 59.09
Current: 10.9

8.33
59.09
POCF 10.64
GILD's POCF is ranked higher than
88% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 31.64 vs. GILD: 10.64 )
Ranked among companies with meaningful POCF only.
GILD' s 10-Year POCF Range
Min: 8.01   Max: 52.27
Current: 10.64

8.01
52.27
EV-to-EBIT 9.42
GILD's EV-to-EBIT is ranked higher than
86% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. GILD: 9.42 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s 10-Year EV-to-EBIT Range
Min: -103.9   Max: 473.4
Current: 9.42

-103.9
473.4
PEG 0.47
GILD's PEG is ranked higher than
94% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. GILD: 0.47 )
Ranked among companies with meaningful PEG only.
GILD' s 10-Year PEG Range
Min: 0.36   Max: 4.23
Current: 0.47

0.36
4.23
Shiller P/E 36.00
GILD's Shiller P/E is ranked higher than
65% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. GILD: 36.00 )
Ranked among companies with meaningful Shiller P/E only.
GILD' s 10-Year Shiller P/E Range
Min: 17.87   Max: 1840.8
Current: 36

17.87
1840.8
Current Ratio 2.70
GILD's Current Ratio is ranked lower than
65% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. GILD: 2.70 )
Ranked among companies with meaningful Current Ratio only.
GILD' s 10-Year Current Ratio Range
Min: 1.09   Max: 20.42
Current: 2.7

1.09
20.42
Quick Ratio 2.44
GILD's Quick Ratio is ranked lower than
65% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. GILD: 2.44 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s 10-Year Quick Ratio Range
Min: 0.83   Max: 20.42
Current: 2.44

0.83
20.42
Days Inventory 178.16
GILD's Days Inventory is ranked lower than
69% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. GILD: 178.16 )
Ranked among companies with meaningful Days Inventory only.
GILD' s 10-Year Days Inventory Range
Min: 148.53   Max: 405.59
Current: 178.16

148.53
405.59
Days Sales Outstanding 64.21
GILD's Days Sales Outstanding is ranked lower than
51% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. GILD: 64.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s 10-Year Days Sales Outstanding Range
Min: 65.89   Max: 115.9
Current: 64.21

65.89
115.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 32.30
GILD's Price/Tangible Book is ranked lower than
104% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. GILD: 32.30 )
Ranked among companies with meaningful Price/Tangible Book only.
GILD' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 131.22
Current: 32.3

2.08
131.22
Price/DCF (Projected) 1.90
GILD's Price/DCF (Projected) is ranked higher than
80% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 1.90 )
Ranked among companies with meaningful Price/DCF (Projected) only.
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 20.81
Current: 1.9

0.77
20.81
Price/Median PS Value 0.70
GILD's Price/Median PS Value is ranked higher than
84% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GILD: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
GILD' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 4.91
Current: 0.7

0.43
4.91
Price/Peter Lynch Fair Value 0.50
GILD's Price/Peter Lynch Fair Value is ranked higher than
97% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GILD: 0.50 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 9.13
Current: 0.5

0.4
9.13
Price/Graham Number 4.10
GILD's Price/Graham Number is ranked higher than
51% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GILD: 4.10 )
Ranked among companies with meaningful Price/Graham Number only.
GILD' s 10-Year Price/Graham Number Range
Min: 1.59   Max: 15.08
Current: 4.1

1.59
15.08
Earnings Yield (Greenblatt) 10.70
GILD's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.60 vs. GILD: 10.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 15
Current: 10.7

0.2
15
Forward Rate of Return (Yacktman) 34.61
GILD's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 14.93 vs. GILD: 34.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.2   Max: 46.1
Current: 34.61

0.2
46.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for GILD

Headlines

Articles On GuruFocus.com
COE May 28 2015 
Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
Top-Ranked Analysts Are Bullish on Gilead Sciences, Inc. (GILD) May 14 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
pharma May 10 2015 
Julian Robertson's growing stocks trading at low P/E May 05 2015 
Gilead Sciences Remains a Popular Biotech Stock Following Earnings May 03 2015 
Looking Ahead of Wall Street: Apple, GoPro, Gilead Sciences Apr 27 2015 
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Weekly CFO Sells Highlight: Gilead Sciences Inc, CarMax Inc, Anthem Inc. Apr 20 2015 

More From Other Websites
Pacira-FDA Meet for Exparel's Nerve Block Label Expansion - Analyst Blog May 29 2015
Here’s another way to spot potential health-care-stock winners May 29 2015
Gilead's New HIV Combination Drug under Review in the EU - Analyst Blog May 29 2015
High Intensity Players: Something's Missing May 29 2015
Gilead Sciences: Hepatitis-C Scripts Decline But Less May 29 2015
Will Gilead's Hepatitis C Dominance Collapse? May 28 2015
Gilead Sciences: Still Opportunity to Grow? May 28 2015
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of... May 28 2015
8:33 am Gilead Sciences announces that the EMA has validated the marketing authorization... May 28 2015
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of... May 28 2015
Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday,... May 27 2015
Gilead cuts ribbon on innovative new laboratory, announces additional $100m investment in Edmonton May 27 2015
Gilead-GlobeImmune Hepatitis B Drug Fails Trial May 27 2015
Gilead Sciences: Does Hepatitis-B Failure Mean More M&A? May 27 2015
As Earnings Shrink, Here’s Where to Hunt for Profits May 27 2015
Should This Figure Worry Gilead Shareholders? May 26 2015
A Sell in May Strategy May 26 2015
5 most popular health-care stocks among hedge funds May 26 2015
5 Most Popular Healthcare Stocks Among Hedge Funds May 26 2015
Consumers Sue Anthem for Denying Coverage for a Gilead Hepatitis C Drug May 26 2015
Large Companies With Fastest Revenue and Earnings Growth in 2015 May 24 2015
Can Gilead keep growing without a big deal? May 23 2015
The Most Loved Biotechs of Big Hedge Funds May 23 2015
Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19 May 18 2015
S&P 500 closes at new record high May 14 2015
Speech given at the 113th Annual General Meeting of DMG MORI SEIKI AKTIENGESELLSCHAFT on 8 May 2015 May 08 2015
Gilead Sciences Acquires EpiTherapeutics May 06 2015
Mylan Launches Gilead Sciences' Sovaldi® Tablets in India May 04 2015
US STOCKS-Wall St rebounds as investors buy beaten-down shares May 01 2015
US STOCKS-Nasdaq snaps four-day losing streak as health stocks rebound May 01 2015
US STOCKS-Wall St opens higher as tech, health stocks rebound May 01 2015
US stocks up as Expedia surges while LinkedIn tanks May 01 2015
Gilead lifted by $3.6B 1Q sales of newest hepatitis C pill Apr 30 2015
Gilead Sciences Declares First Quarterly Cash Dividend Apr 30 2015
Gilead Sciences Announces First Quarter 2015 Financial Results Apr 30 2015
Gilead beats Street 1Q forecasts Apr 30 2015
Merck hurdles Wall Street forecasts Apr 28 2015
Aetna raises 2015 outlook after 1Q earnings tops forecasts Apr 28 2015
Merck tops Street 1Q forecasts Apr 28 2015
US stocks snap record-setting rally Apr 27 2015
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C... Apr 25 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015 Apr 23 2015
IMS: US prescription drug spending jumped 13 pct. in 2014 Apr 14 2015
U.S. prescription drug spending rose 13 pct in 2014-IMS report Apr 13 2015
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination... Apr 07 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
US STOCKS-Wall St little changed as energy retreats Mar 23 2015
US STOCKS-Wall St little changed as energy pares gains Mar 23 2015
US stocks mixed as Gilead Sciences and Monsanto fall Mar 23 2015
US STOCKS-Stocks up as dollar adds to losses, oil gains Mar 23 2015
US stocks mixed; Gilead Sciences, Monsanto fall Mar 23 2015
US STOCKS-Wall St to dip at the open after weekly gains; volatility eyed Mar 23 2015
US stocks mixed as Gilead Sciences and Monsanto fall Mar 22 2015
DMG MORI – 2014 the best year in the company history Record results in order intake, sales... Mar 12 2015
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11 Mar 10 2015
Change of offer conditions Mar 09 2015
DMG MORI SEIKI AKTIENGESELLSCHAFT and DMG MORI SEIKI CO., LTD. agree on change of the offer... Mar 09 2015
UK cost body backs Gilead's pricey combination hepatitis pill Mar 02 2015
Natco Pharma ties up with Gilead on hepatitis C drugs Mar 02 2015
Natco Pharma ties up with Gilead on hepatitis C drugs Mar 02 2015
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India Feb 27 2015
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing... Feb 26 2015
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic... Feb 26 2015
Preventative treatment dramatically reduces HIV risk in gay men Feb 24 2015
Gilead agrees 41,000 eur hep-C drug price for 12 week treatment Feb 12 2015
Competition, discount worries weigh on Gilead shares Feb 04 2015
Hepatitis C drugs market sees Gilead emerge as leading global player Feb 03 2015
Gilead 4Q results top estimates, company plans $15B buyback Feb 03 2015
Gilead beats Street 4Q forecasts Feb 03 2015
Gilead tops Street 4Q forecasts Feb 03 2015
German insurers win discounts on Gilead's Sovaldi Jan 24 2015
AbbVie's new hepatitis C treatment gets approval in EU Jan 19 2015
Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's Jan 16 2015
Ahead of the Bell: Drugmaker AbbVie's shares slip Jan 09 2015
Gilead Sciences to buy liver disease treatment from Phenex Jan 06 2015
Gilead climbs after CVS Health favors its hepatitis C drugs Jan 05 2015
US STOCKS-Futures point to lower open after S&P 500 closing record Dec 30 2014
US STOCKS-Wall St little changed but S&P hits record Dec 29 2014
US STOCKS-Wall St little changed as energy pares gains Dec 29 2014
US STOCKS-Wall St edges up in quiet session Dec 29 2014
Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others Sep 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK